The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
Prevalence of hepatitis C (HCV) among people who inject drugs in Europe is very high – in excess of 50% across six countries in the region and an estimated 84% in Portugal. But a new report released by EU drug body for World Hepatitis Day (July 28), shows that a combination of new treatments and prevention interventions gives significant reason for optimism in curbing the HCV epidemic among drug users in the region.
An injectable version of the opiate substitution treatment (OST) buprenorphine – which is delivered through an implant – has been approved for use in the USA by the Food and Drug Administration (FDA).
The number of new HIV infections in the USA has fallen by 11% between 2010 and 2015, however the rate of decline falls far short of the goals set in the 2010-2015 National HIV/AIDS Strategy (NHAS).
Rural and suburban areas of the United States of America are lacking the harm reduction services needed to support increasing numbers of people who inject drugs.
